Dr. Hanke: Yes, the JDD does fill a gap. The gap was identified by Dr. Perry Robins who has initiated many successful projects in dermatology including Dermatologic Surgery (formerly the Journal of Dermatologic Surgery and Oncology), the Skin Cancer Foundation, the International Society for Dermatologic Surgery, and Dermatology-in-Review, to name a few.
Dr. Hanke: The content of the Journal provides a great mix of medical dermatology, dermatologic oncology, dermatologic surgery, and cosmetic medicine/cosmetic surgery. I am interested in all these subject areas, so I tend to at least scan all the articles. Manuscripts from Europe and other parts of the world provide a different perspective. The many articles on clinical trials and new drugs and devices are especially appreciated.
Dr. Hanke: The Journal has grown in terms of both quantity and quality of manuscripts. I am certain that some authors submit to the JDD because of the relatively short publication time compared to other dermatology journals. All of us who perform reviews for other dermatology journals know that many good manuscripts are commonly rejected even thus they may be of a publishable quality. The names of many well-respected leaders in dermatology can be found as authors and coauthors on JDD articles.
Dr. Hanke: The special issues of JDD provide comprehensive coverage of various subjects. The guest editors of the special issues are leaders in their respective fields, and they take their assignments seriously.
Dr. Hanke: The distribution of e-JDD to 23,000 dermatologists around the world enhances the reputation of the Journal in many ways. The e-subscription allows dermatologists in less-developed countries to participate in advances in dermatology at minimal cost. JDD has been a fully indexed medical journal from the onset so that published manuscripts are searchable in the medical literature.
Dr. Hanke: A good deal of thought by the editorial staff and editors goes into the organization and planning of the Journal. I especially like seeing the early results of clinical trials often long before drugs are approved in the US. Hopefully early publication of the results of trials will lead to more new drugs in dermatology.